Congress shields FDA whistleblowers
The House of Representatives passes an amendment March 14 to H.R. 985, which shields whistleblowers who report tampering with government scientific investigations. The amendment, proposed by Rep. Bart Stupak, D-MI., will "enhance whistleblower protection by including in the list of reportable actions any attempt to suppress the right of government scientists to publish or announce their findings in peer reviewed journals or public meetings with their fellow scientists." Stupak cites a Union of Concerned Scientists survey, finding that of the 997 FDA scientists who responded, 36 percent did not feel they could openly express concerns within the agency about public health without fear of retaliation (1"The Pink Sheet" July 24, 2006, p. 16)...
You may also be interested in...
FDA scientists fear retaliation for expressing health concerns to the public, according to results of a Union of Concerned Scientists survey released July 20
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.